China’s decision to abandon its zero-COVID policy to supress the spread of the SARS-CoV-2 virus helped drive up Haleon’s sales in the first half of 2023. And the company sees runway for continued growth in its second-largest market by sales.
Haleon’s group turnover advanced by 10.6% to £5.74bn ($7
Two of its biggest brands in China, the Fenbid analgesic and Contac cold & flu line, experienced a “massive” spike in demand as an end to ZERO-COVID brought with it